SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.86+0.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert S. who wrote (6873)8/1/1998 10:58:00 AM
From: Tharos  Read Replies (1) of 17367
 
What leap of "logic" did you use to conclude that because Bayer AG is not on bended knee swearing fidelity to Xoma it finds Xoma's products of no interest? And given Xoma's Neuprex is not yet approved by the FDA because it is a new and novel approach for treating meningitis, what makes you conclude that it is not a new and novel way to treat sepsis?

Lets see now, a top of the line pharmaceutical company with hundreds of products and $billions in resources is looking for resources and support for new ideas that will help shape the future of the treatment and management of sepsis and septic shock and you see this as a non confidence vote for Xoma because:
1. you somehow think if Bayer thought Xoma's Neuprex was the answer for all possible causes of sepsis it would not seek out new sources?
2. a pharmaceutical company should look only to one biotech firm for all of its answers?
3. you are scratching for any way to cast a shadow on Xoma?
4. you have your head so far up you butt you are unable to pull it out so you can take time to study pharmaceutical companies and biotech firms?
5. Neuprex has been on the market for so long now that it is not new or novel?

I'm betting the answer is #3, but it would seem #4 is a close second.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News